Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001209782 | SCV001381232 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2022-07-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 940241). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 2750 of the BRCA2 protein (p.Lys2750Gln). |
Ambry Genetics | RCV004601389 | SCV005102145 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-09 | criteria provided, single submitter | clinical testing | The p.K2750Q variant (also known as c.8248A>C), located in coding exon 17 of the BRCA2 gene, results from an A to C substitution at nucleotide position 8248. The lysine at codon 2750 is replaced by glutamine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |